Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v1-EN
Language French English
Date Updated 2017-09-13 2017-08-18
Drug Identification Number 02312557 02312557
Brand name BOOSTRIX-POLIO BOOSTRIX-POLIO
Common or Proper name Combined diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine Combined diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine
Company Name GLAXOSMITHKLINE INC GLAXOSMITHKLINE INC
Ingredients INACTIVATED POLIOVIRUS TYPE I INACTIVATED POLIOVIRUS TYPE II INACTIVATED POLIOVIRUS TYPE III TETANUS TOXOID ADSORBED DIPHTHERIA TOXOID ADSORBED PERTUSSIS TOXOID ADSORBED FILAMENTOUS HAEMAGGLUTININ ADSORBED PERTACTIN ADSORBED INACTIVATED POLIOVIRUS TYPE I INACTIVATED POLIOVIRUS TYPE II INACTIVATED POLIOVIRUS TYPE III TETANUS TOXOID ADSORBED DIPHTHERIA TOXOID ADSORBED PERTUSSIS TOXOID ADSORBED FILAMENTOUS HAEMAGGLUTININ ADSORBED PERTACTIN ADSORBED
Strength(s) 40D 8D 32D 5.0LF 2.5LF 8MCG 8MCG 2.5MCG 40D 8D 32D 5.0LF 2.5LF 8MCG 8MCG 2.5MCG
Dosage form(s) SUSPENSION SUSPENSION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 10's 10's
ATC code J07CA J07CA
ATC description BACTERIAL AND VIRAL VACCINES, COMBINED BACTERIAL AND VIRAL VACCINES, COMBINED
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date 2017-09-21 2017-09-14
Actual start date
Estimated end date Unknown Unknown
Actual end date
Shortage status Anticipated shortage Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments